Fluorescent Viability Stains to Probe the Metabolic Status of Aflatoxigenic Fungus in Dual Culture of Aspergillus flavus and Pichia anomala
- 337 Downloads
The metabolic activity of the aflatoxigenic fungus, Aspergillus flavus co-cultured with the biocontrol yeast, Pichia anomala was examined using several viability stains. Both the FUN-1 stain and the combined use of DiBAC4(5) with CDFA-AM stains were applied in this study. The results suggest that the ATP-generating system in A. flavus was inactivated as the ratio of yeasts to fungi increased in the dual culture. A decrease in hyphal membrane potential and esterase activity was substantiated by the combined stains of DiBAC4(5) and CDFA-AM. Reduced metabolic function in conjunction with cell wall damage of A. flavus hindered the growth and biomass production of this fungus. Viability stains such as FUN-1 and DiBAC4(5) with CDFA-AM may assist in elucidating the biocontrol mechanism by allowing for the visualization of the antagonistic effect of yeast species on target fungi in situ, as well as for screening potent biocontrol yeast agents against fungal pathogens.
KeywordsAflatoxin Yeast Fungus Fluorescence Mechanism of biocontrol
We thank Thomas McKeon. Glenn Barley and Bruce C. Campbell for their comments and reviews of the manuscript.
- 5.Marr KA, Koudadoust M, Black M, Balajee SA. Early events in macrophage killing of Aspergillus fumigatus conidia: new flow cytometric viability assay. Clin Diag Lab Immunol. 2001;8:1240–7.Google Scholar
- 15.Scudamore KA. Aspergillus toxin in food and animal feeding stuffs. In: Powell KA, Renwick A, Peberdy JF, editors. The genus Aspergillus. New York: Plenum Press; 1994. p. 59–71.Google Scholar
- 16.Commission of the European Community. Commission Directive 98/53/EC of July 1998 laying down the sampling methods and the methods of analysis for the official control of the levels of certain contaminants in food stuffs. Off Eur Communities Legislation. 1998; L201:93–101.Google Scholar
- 17.U. S. Food and Drug Administration. Compliance policy guides manual. Washington, DC: U. S. FDA; 1996. Sec. 555.400, 268; Sec. 570.500, 299.Google Scholar